GlassScriptPhysician profile
Austin R Schlie
NPI 1871721332
$10,795.89
in general payments reported to CMS, 2019-2025
49 companies · $2,150 in 2025
The $2,150 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $776 · 2020: $1,074 · 2021: $1,360 · 2022: $1,614 · 2023: $1,602 · 2024: $2,220 · 2025: $2,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,842 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,841.54 |
| Education | $130.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,711.59 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,477.99 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $963.26 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Corium, LLC | $856.63 | 2022-2025 | Azstarys |
| Pfizer INC. | $729.54 | 2019-2025 | |
| Amgen INC. | $581.37 | 2019-2025 | Repatha, Repatha, Otezla |
| Glaxosmithkline, LLC. | $544.00 | 2019-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $509.97 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.21 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $227.86 | 2019-2024 | |
| Amarin Pharma, INC. | $225.70 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $206.01 | 2022-2025 | |
| Allergan, INC. | $186.21 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $167.27 | 2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $150.76 | 2023-2025 | Auvelity, Sunosi |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Schlie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.